Compare · BEAT vs RMD
BEAT vs RMD
Side-by-side comparison of Heartbeam Inc. (BEAT) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BEAT and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.86B, about 930.3x BEAT ($31.0M).
- Over the past year, BEAT is down 57.2% and RMD is down 23.8% - RMD leads by 33.4 points.
- RMD has been more active in the news (7 items in the past 4 weeks vs 4 for BEAT).
- RMD has more recent analyst coverage (25 ratings vs 9 for BEAT).
- Company
- Heartbeam Inc.
- ResMed Inc.
- Price
- $0.56-3.08%
- $198.99-1.86%
- Market cap
- $31.0M
- $28.86B
- 1M return
- -24.92%
- +2.60%
- 1Y return
- -57.16%
- -23.76%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 4
- 7
- Recent ratings
- 9
- 25
Heartbeam Inc.
HeartBeam, Inc., a medical technology company, primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease. It focuses on providing diagnostic data to help physicians with care management of patients with cardiovascular disease. The company is developing its telehealth product that comprises a credit card sized electrocardiograms machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is based in Santa Clara, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest BEAT
- Maxim Group initiated coverage on HeartBeam with a new price target
- HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device
- Heartbeam Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule
- SEC Form DEFA14A filed by Heartbeam Inc.
- Heartbeam Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition
- Heartbeam Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form DEF 14A filed by Heartbeam Inc.
- SEC Form PRE 14A filed by Heartbeam Inc.
Latest RMD
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
- ResMed downgraded by Morgan Stanley with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)